
<script type="text/javascript">
<!--
document.write('<div id="oa_widget"></div>');
document.write('<script type="text/javascript" src="https://www.openaire.eu/index.php?option=com_openaire&view=widget&format=raw&projectId=undefined&type=result"></script>');
-->
</script>pmid: 17013433
Neuropsychiatric involvement in patients with Systemic Lupus Erythematosus (SLE), first mentioned by Kaposi more than 100 years ago, still remains one of the main challenge facing rheumatologist and other physicians. The diagnosis of neuropsychiatric SLE (NPSLE) is complex not only because of the considerable prevalence variation (14-80%) but also because of the wide spectrum of NP manifestations. They vary from overt neurologic alterations (seizure, psychosis), to subtle abnormalities (neurocognitive dysfunctions). Different NP manifestations result from a variety of mechanisms including antibodies, vasculitis, thrombosis, hemorrhages and cytokine-mediated damages. Of note, despite the dramatic clinical manifestations, too often changes at the morphological neuroimaging techniques are minimal and non specific. There is no one diagnostic tool specific for NPSLE and diagnosis must be based on the combinated use of immunoserological tests, functional and anatomical neuroimaging and standardized specific criteria. Symptomatic, immunosuppressive and anticoagulant therapies are the main strategies available in the management of these patients. Therapy for CNS lupus should be adjusted according to the needs of the individual patients. The coming years promise to be an important time for the development of new neuroimaging techniques and for the study of disease mechanism. An early and objective identification of brain involvement will allow for appropriate treatment to avoid severe complications.
Neuroinformatics, Magnetic Resonance Spectroscopy, Sensitivity and Specificity, Diagnosis, Differential, Rheumatology, Prevalence, Humans, Medical History Taking, Internal medicine, Cyclophosphamide, Lupus Vasculitis, Central Nervous System, R, Plasmapheresis, RC31-1245, Magnetic Resonance Imaging, Methotrexate, Anti-Anxiety Agents, Antirheumatic Agents, Antibodies, Antiphospholipid, Medicine, Tomography, X-Ray Computed, Immunosuppressive Agents, Antipsychotic Agents
Neuroinformatics, Magnetic Resonance Spectroscopy, Sensitivity and Specificity, Diagnosis, Differential, Rheumatology, Prevalence, Humans, Medical History Taking, Internal medicine, Cyclophosphamide, Lupus Vasculitis, Central Nervous System, R, Plasmapheresis, RC31-1245, Magnetic Resonance Imaging, Methotrexate, Anti-Anxiety Agents, Antirheumatic Agents, Antibodies, Antiphospholipid, Medicine, Tomography, X-Ray Computed, Immunosuppressive Agents, Antipsychotic Agents
| citations This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | 9 | |
| popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network. | Average | |
| influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | Average | |
| impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network. | Top 10% |
